Karyopharm Therapeutics Inc.
KPTI
$5.59
-$0.23-3.95%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
10/10/2025
-
MarketBeat
10/10/2025
-
MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Brokerages
10/10/2025
-
Ticker Report
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Brokerages
10/10/2025
-
MarketBeat
10/10/2025
-
TipRanks Financial Blog
10/9/2025
-
MarketBeat
10/8/2025
-
MarketBeat
10/8/2025
-
RTT News - Momentum Stocks
10/8/2025
-
GuruFocus
10/8/2025
-
PR Newswire
10/7/2025
-
MarketBeat
10/3/2025
-
TipRanks Financial Blog
10/2/2025
-
GuruFocus
10/1/2025
-
PR Newswire
9/28/2025
-
MarketBeat
9/27/2025
-
MarketBeat
9/26/2025
-
MarketBeat
9/23/2025
-
Ticker Report
9/11/2025
-
Simply Wall St
9/10/2025
-
PR Newswire
9/10/2025
-
MarketBeat
9/4/2025
-
MarketBeat
9/3/2025
-
ETF Channel
9/2/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, August 11, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 658 0600
Address
85 Wells Avenue
Newton, MA 02459-3298
Newton, MA 02459-3298
Country
Year Founded
Business Description
Sector
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other...
more